A Phase 3 2-Part Open-label Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to learn more about the safety and effects ivacaftor has in children with certain forms of cystic fibrosis who are less than 24 months of age when treatment begins.
Description
The purpose of this study is to learn more about the safety and effects ivacaftor has in children with certain forms of cystic fibrosis who are less than 24 months of age when treatment begins.
Details
| Condition | cystic fibrosis |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX6884 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.